R code for cost-effectiveness model evaluating directly acting oral anticoagulants (DOACs) for prevention of stroke in atrial fibrillation.

To use, move the .R files to a "code" directory and that data files to a "data" directory. Everything can then be run from NOAC.AF.model.main.3.R

This research was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme project number 11/92/17 and NIHR Senior Investigator award NF-SI-0611-10168.

Support for R in CEA provided by MRC Hubs for Trials Methodology Research ConDuCT-II (Collaboration and innovation in Difficult and Complex randomised controlled Trials In Invasive procedures) hub

Howard Thom 31-October-2018. Bristol Medical School: Population Health Sciences. Bristol University, UK. howard.thom@bristol.ac.uk

Details of model described in two publications:

Sterne JA, Bodalia PN, Bryden PA, Davies PA, Lopez-Lopez JA, Okoli GN, et al. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017; 21(9):1-386.

Lopez-Lopez JA, Sterne J, Thom H, Higgins J, Hingorani A, Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017; 359(J5058).